Dolo

This research investigates patients with newly diagnosed oligometastatic prostate cancer OMPCa who meet the CHAARTED criteria for low metastatic volume disease. The study aims to collect data in a registry from major urological centers in the Triveneto region to evaluate how local treatments, such as surgery or radiotherapy of the primary tumor, combined with systemic hormonal therapies, affect cancer outcomes and quality of life. Patients with high volume metastatic disease, defined by specific bone and visceral metastases criteria, are excluded from this study. The study is observational and involves patients receiving local treatment for their primary prostate cancer along with systemic hormonal therapy, which may be androgen deprivation therapy ADT alone or combined with other agents like Docetaxel or androgen receptor signal inhibitors ARTA. Participants will be followed to observe outcomes without randomization or comparison groups since this is a single-arm study. Participants will be monitored for overall survival, cancer-specific survival, progression to castration-resistant prostate cancer, radiological progression, quality of life, as well as treatment complications for up to three years. Data collection includes clinical assessments and quality of life evaluations from the start of treatment through follow-up. The study helps track how these treatments impact patients over time in routine clinical practice.